Alps Advisors Inc. grew its holdings in Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) by 30.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 35,572 shares of the biopharmaceutical company’s stock after acquiring an additional 8,378 shares during the quarter. Alps Advisors Inc. owned 0.23% of Madrigal Pharmaceuticals worth $4,010,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Capital Research Global Investors raised its stake in Madrigal Pharmaceuticals by 21.5% in the third quarter. Capital Research Global Investors now owns 1,664,452 shares of the biopharmaceutical company’s stock valued at $356,409,000 after purchasing an additional 294,200 shares in the last quarter. Vanguard Group Inc raised its stake in Madrigal Pharmaceuticals by 52.7% in the third quarter. Vanguard Group Inc now owns 706,318 shares of the biopharmaceutical company’s stock valued at $151,243,000 after purchasing an additional 243,664 shares in the last quarter. Vanguard Group Inc. raised its stake in Madrigal Pharmaceuticals by 52.7% in the third quarter. Vanguard Group Inc. now owns 706,318 shares of the biopharmaceutical company’s stock valued at $151,243,000 after purchasing an additional 243,664 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Madrigal Pharmaceuticals in the third quarter valued at about $20,300,000. Finally, BlackRock Inc. raised its stake in Madrigal Pharmaceuticals by 17.7% in the third quarter. BlackRock Inc. now owns 575,019 shares of the biopharmaceutical company’s stock valued at $123,130,000 after purchasing an additional 86,520 shares in the last quarter. 56.07% of the stock is owned by institutional investors.

Shares of NASDAQ MDGL opened at $116.36 on Friday. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -45.81 and a beta of 1.22. Madrigal Pharmaceuticals Inc has a 12 month low of $91.56 and a 12 month high of $325.98.

A number of research analysts recently commented on the company. B. Riley assumed coverage on Madrigal Pharmaceuticals in a research note on Tuesday, December 11th. They issued a “neutral” rating and a $124.00 price target for the company. Oppenheimer set a $200.00 price target on Madrigal Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 4th. BidaskClub downgraded Madrigal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 17th. Wolfe Research assumed coverage on Madrigal Pharmaceuticals in a research note on Friday, December 14th. They issued an “outperform” rating for the company. Finally, ValuEngine raised Madrigal Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 31st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $235.30.

In other Madrigal Pharmaceuticals news, Director Fred B. Craves bought 2,000 shares of the stock in a transaction on Monday, November 19th. The stock was purchased at an average price of $124.69 per share, with a total value of $249,380.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Paul A. Friedman bought 4,000 shares of the stock in a transaction on Monday, November 19th. The shares were acquired at an average cost of $124.00 per share, with a total value of $496,000.00. The disclosure for this purchase can be found here. 56.70% of the stock is currently owned by insiders.

WARNING: This report was reported by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2019/02/10/alps-advisors-inc-acquires-8378-shares-of-madrigal-pharmaceuticals-inc-mdgl.html.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

See Also: How to Profit and Limit Losses With Stop Orders

Institutional Ownership by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.